|Bid||3.2000 x 900|
|Ask||3.8000 x 1800|
|Day's Range||3.3400 - 3.8800|
|52 Week Range||1.7600 - 7.0700|
|Beta (5Y Monthly)||2.53|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 30, 2020 - May 04, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.70|
Benchmarks ended were mixed on Friday, as investors' attention was fixed on the rising death toll in China and the limited strength displayed by American consumers last month.
ImmunoGen (IMGN) delivered earnings and revenue surprises of 160.00% and 53.43%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mark Enyedy became the CEO of ImmunoGen, Inc. (NASDAQ:IMGN) in 2016. First, this article will compare CEO compensation...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 22) 10X Genomics Inc (NASDAQ: TXG ) Abbott Laboratories ...
FDA approves a new pivotal study to support accelerated approval pathway for ImmunoGen's (IMGN) ovarian cancer candidate, mirvetuximab soravtansine.
These four stocks are moving on news and gaining technical momentum: Axsome Therapeutics, Inc . (NASDAQ: AXSM ) jumped $8.60 to $89.57 on 2.6 million shares Wednesday, more than double its average volume. ...
FDA approves a new pivotal study to support accelerated approval pathway for ImmunoGen's (IMGN) ovarian cancer candidate, mirvetuximab soravtansine. Shares up.
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Our research shows that most of the stocks that smart money likes historically generate strong […]
ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Roche's (RHHBY) breast cancer candidate and lymphona candidate get positive CHMP opinion. The company inks a deal to acquire Promedior, Inc.
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
A look at the shareholders of ImmunoGen, Inc. (NASDAQ:IMGN) can tell us which group is most powerful. Insiders often...
ImmunoGen (IMGN) reports narrower-than-expected third-quarter loss and beats revenue estimates. The company is set to initiate the FDA recommended phase III study on mirvetuximab soravtansine by year-end.